Popular Trials
INCB057643 +/- Ruxolitinib for Myelofibrosis
This trial is testing a new drug called INCB057643, alone or with ruxolitinib, for patients with certain blood cancers like myelofibrosis. The goal is to see if it can stop cancer growth or help other treatments work better. Ruxolitinib has been approved for the treatment of myelofibrosis and has shown clinical benefits in reducing symptoms and improving survival.
Selective Inhibitor of Nuclear Export (SINE)
Selinexor for Myelofibrosis
This trial is testing selinexor, a medication that may help treat certain blood disorders. It focuses on patients with primary or secondary myelofibrosis who do not respond to or cannot tolerate common treatments like ruxolitinib. Selinexor works by blocking a protein that helps harmful cells grow and survive. Selinexor is the first oral selective inhibitor of nuclear export compound tested for cancer treatment.
JAK Inhibitor
MMB for Myelofibrosis
This trial aims to provide ongoing access to momelotinib for patients with certain types of myelofibrosis who are already taking the drug and have not seen their disease get worse. The study will also look at how long these patients live without developing leukemia. Momelotinib has been studied for myelofibrosis and other related conditions.
Alkylating agents
Topotecan + Carboplatin + Veliparib for Leukemia
This trial is testing how well topotecan hydrochloride, carboplatin, and veliparib work in treating patients with myeloproliferative disorders and acute myeloid leukemia or chronic myelomonocytic leukemia.
Popular Filters
Trials for Myelofibrosis Patients
Epigenetic Modulator
Bomedemstat for Blood Disorders
"This trial aims to continue monitoring participants who have been taking bomedemstat for a while to gather information on its long-term safety and effectiveness. Participants must have been using bomedemstat for at
Histone Deacetylase Inhibitor
PXS-5505 for Myelofibrosis
This trial tests a new drug, PXS-5505, for safety and tolerance in patients with specific bone marrow disorders. It aims to find the best dose and see if combining it with another medication improves treatment.
JAK2 Inhibitor
Pacritinib for Myelofibrosis
This trial is testing a new drug, pacritinib, to see if it is better than the current standard of care for treating patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have severe thrombocytopenia (low platelet count). 399 patients will be enrolled and randomly assigned to either pacritinib or the current standard of care. The primary outcome measure is spleen response rate.
Chemotherapy
INCB000928 + Ruxolitinib for Myelofibrosis
This trial is testing a new drug called INCB000928, either alone or with ruxolitinib, to see if it is safe and effective. It targets people with Myelofibrosis who need regular blood transfusions or have severe anemia. The goal is to see if the drug can reduce the need for transfusions and improve anemia symptoms.
Anti-metabolites
Decitabine + JAK Inhibitors for Advanced Myeloproliferative Disorders
This trial looks at whether a combination of decitabine, ruxolitinib, and fedratinib may be more effective than chemotherapy or no treatment in patients with myeloproliferative neoplasms.
Trials for ET Patients
Epigenetic Modulator
Bomedemstat for Blood Disorders
"This trial aims to continue monitoring participants who have been taking bomedemstat for a while to gather information on its long-term safety and effectiveness. Participants must have been using bomedemstat for at
Interferon
Ropeginterferon Alfa-2b for Essential Thrombocythemia
This trial is testing a new drug, P1101, to see if it is more effective and has fewer side effects than the current standard drug, ANA, for treating people with essential thrombocythemia who have not responded well to hydroxyurea.
PARP Inhibitor
Veliparib + Topotecan ± Carboplatin for Leukemia
This trial is studying the side effects and best dose of veliparib when given with topotecan hydrochloride and carboplatin in treating patients with relapsed or refractory acute leukemia, high-risk myelodysplasia, or aggressive myeloproliferative disorders.
Phase 3 Trials
Epigenetic Modulator
Bomedemstat for Blood Disorders
"This trial aims to continue monitoring participants who have been taking bomedemstat for a while to gather information on its long-term safety and effectiveness. Participants must have been using bomedemstat for at
Interferon
Ropeginterferon Alfa-2b for Essential Thrombocythemia
This trial is testing a new drug, P1101, to see if it is more effective and has fewer side effects than the current standard drug, ANA, for treating people with essential thrombocythemia who have not responded well to hydroxyurea.
JAK2 Inhibitor
Pacritinib for Myelofibrosis
This trial is testing a new drug, pacritinib, to see if it is better than the current standard of care for treating patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have severe thrombocytopenia (low platelet count). 399 patients will be enrolled and randomly assigned to either pacritinib or the current standard of care. The primary outcome measure is spleen response rate.
Small Molecule Inhibitor
KRT-232 for Myelofibrosis
This trial will study KRT-232, a new drug that inhibits MDM2, for the treatment of patients with myelofibrosis who are no longer benefiting from treatment with a JAK inhibitor. The trial will be conducted in 2 phases.
Bromodomain and Extra-Terminal Protein Inhibitor
Pelabresib for Myelofibrosis
This trial tests a new drug combination of pelabresib and ruxolitinib in patients with myelofibrosis who haven't tried certain treatments before. Pelabresib blocks harmful proteins, and ruxolitinib stops harmful signals to see if this combination works better.
Trials With No Placebo
Epigenetic Modulator
Bomedemstat for Blood Disorders
"This trial aims to continue monitoring participants who have been taking bomedemstat for a while to gather information on its long-term safety and effectiveness. Participants must have been using bomedemstat for at
Histone Deacetylase Inhibitor
PXS-5505 for Myelofibrosis
This trial tests a new drug, PXS-5505, for safety and tolerance in patients with specific bone marrow disorders. It aims to find the best dose and see if combining it with another medication improves treatment.
Interferon
Ropeginterferon Alfa-2b for Essential Thrombocythemia
This trial is testing a new drug, P1101, to see if it is more effective and has fewer side effects than the current standard drug, ANA, for treating people with essential thrombocythemia who have not responded well to hydroxyurea.
View More Related Trials
Frequently Asked Questions
Introduction to essential thrombocythemia
What are the top hospitals conducting essential thrombocythemia research?
When it comes to cutting-edge clinical trials focused on essential thrombocythemia, several top hospitals are leading the way. In Ann Arbor, Michigan, the University of Michigan is at the forefront with three active trials dedicated to this condition and a total of ten previous studies. Their commitment to advancing our understanding of essential thrombocythemia began in 2011 when they recorded their first trial. Meanwhile, in Houston, Texas, two renowned institutions are making significant contributions as well. The University of Texas MD Anderson Cancer Center has two ongoing essential thrombocythemia trials and a solid track record of seven past studies since their inaugural trial in 2014. Another notable presence is the MD Anderson Cancer Center located in Houston too where they currently have two active essential thrombocythemia trials building upon their twelve previous investigations which dates back till2007.The Icahn School of Medicine at Mount Sinai in New york joins this esteemed group with two ongoing clinical trials for essential thrombocythemia and an impressive history that includes eighteen completed studies since 2007.Further adding depth to these research efforts,Fred Hutchinson Cancer Research Center based out Seattlealso contributes significantly through its current participationin two trails surrounding the condition while having executed seven such tests on patients relatedto this ailment ever since year 2007.
These top-tier hospitals not only offer hope for those affected by essential thrombocythemia but also serve as beacons of medical progress across different regions.Highlights from these centers illustrate that despite being a relatively rare blood disorder characterized by excessive platelet production,the collective endeavors towards understanding and treatingessential trombocthemiaspans across diverse geographic locations;the tireless dedication displayedby multiple institutionsspeaks volumes abouttheir resolveintendingtopaving new avenuesfor improved treatmentthat guaranteea better qualityof life foraffected individuals aroundtheworld
Which are the best cities for essential thrombocythemia clinical trials?
When it comes to essential thrombocythemia clinical trials, several cities emerge as leaders in research and development. New york, Ann Arbor, Houston, San Antonio, and Montreal all have active trials focused on advancing our understanding and treatment of this condition. These trials investigate promising therapies such as FEDRATINIB, Ropeginterferon alfa-2b, KRT-232, Bomedemstat, PXS-5505, IMG-7289 and Pacritinib. With a combined total of 27 ongoing studies across these cities alone, individuals with essential thrombocythemia can access cutting-edge clinical trials that may lead to improved outcomes and quality of life.
Which are the top treatments for essential thrombocythemia being explored in clinical trials?
Exciting developments in essential thrombocythemia research have brought forward several potential treatments currently being explored in clinical trials. Leading the charge is IMG-7289, which has shown promise in two active trials and features prominently among the three all-time essential thrombocythemia trials since its introduction in 2017. Another contender making waves is bomedemstat, currently involved in one active trial and appearing on two all-time essential thrombocythemia studies list, having made its debut just last year. Also gaining attention is PXS-5505, with one ongoing trial dedicated to exploring its efficacy against this condition since its listing earlier this year. Last but not least is KRT-232, featured in one active trial and included within three crucial all-time essential thrombocythemia studies after hitting the scene back in 2019. These innovative treatment options offer hope to patients battling essential thrombocythemia as researchers continue their relentless pursuit of effective solutions for this rare blood disorder.
What are the most recent clinical trials for essential thrombocythemia?
Exciting advancements are underway in the field of essential thrombocythemia, with recent clinical trials shedding light on potential treatments. One such trial focuses on bomedemstat, a promising drug being evaluated for its effectiveness against this condition. Another study investigates the use of PXS-5505 as a treatment option, aiming to improve patient outcomes and quality of life. Additionally, KRT-232 is undergoing testing to determine its efficacy in addressing essential thrombocythemia. These studies represent significant strides towards finding better therapeutic options for individuals affected by this disorder.
What essential thrombocythemia clinical trials were recently completed?
Recently conducted clinical trials have contributed to the advancement of treatments for essential thrombocythemia, a rare disorder characterized by an excess of platelets in the blood. Notably, John Mascarenhas led a trial exploring the potential of AVID200 and completed it in February 2019. Similarly, Imago BioSciences concluded their investigation into IMG-7289 in July 2017. Additionally, M.D. Anderson Cancer Center wrapped up their study on Smac Mimetic LCL161 back in December 2014. These important trials signify ongoing efforts to improve outcomes and quality of life for individuals affected by essential thrombocythemia.